Article info
PDFLaboratory science
Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma
- Correspondence to Dr Seema Sen, Ocular Pathology, Dr.R.P.Centre, All India Institute of Medical Sciences, New Delhi 110029, India; ssenop{at}rediffmail.com
Citation
Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma
Publication history
- Received September 25, 2018
- Revised February 16, 2019
- Accepted March 9, 2019
- First published April 2, 2019.
Online issue publication
May 04, 2023
Article Versions
- Previous version (4 May 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.